We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Beckman Coulter Diagnostics and COPAN Announce Expansion of Distribution Agreement
News

Beckman Coulter Diagnostics and COPAN Announce Expansion of Distribution Agreement

Beckman Coulter Diagnostics and COPAN Announce Expansion of Distribution Agreement
News

Beckman Coulter Diagnostics and COPAN Announce Expansion of Distribution Agreement

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Beckman Coulter Diagnostics and COPAN Announce Expansion of Distribution Agreement"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Beckman Coulter Diagnostics and COPAN have announced that Beckman Coulter Diagnostics and COPAN Group have entered into an amendment to their distribution agreement that expands their relationship into new products and geographic territories.

Additional products include COPAN’s WASPLab automated, front‐end robotic specimen processing, full lab automation and digital microbiology system. The amendment grants Beckman Coulter distribution rights in 21 global markets, including a number of territories in North America, Asia (including, among other territories, Japan and China), Europe, South America and many emerging markets.

“We’re very excited to expand our relationship with COPAN to offer clinical microbiology
laboratories an extended portfolio of products to help provide physicians with the critical information they need regarding bacteria resistance,” said Arnd Kaldowski, president, Beckman Coulter Diagnostics.

Kaldowski continued, “COPAN’s products complement our newly acquired MicroScan brand of microbiology solutions and offer hospitals and private laboratories a complete solution which streamlines workflow—demonstrating Beckman Coulter’s commitment to growth and investment in this new area of our business.”

Stefania Triva, COPAN Group’s CEO said, “This is a new step in the collaboration between the two companies and we look forward to continue working together to expand our reach.” Norman Sharples, Executive VP and Co‐Founder of COPAN Diagnostics, Inc. added, “COPAN has always been committed to provide open platform solutions to our customers and this partnership is further evidence and reinforcement of our ability to integrate and interface with important platforms in microbiology.”

In addition to WASPLab, the amendment allows Beckman Coulter to distribute COPAN’s CTracer, SYNAPSEPro MINI and MALDI‐Trace products.

Advertisement